[Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy]
DOI:
https://doi.org/10.7175/fe.v18i1S.1300Keywords:
Nintedanib, Idiopathic pulmonary fibrosis, Health Technology Assessment, Cost-Utility Analysisology Assessment, Cost-Utility AnalysisAbstract
To date, there are few therapeutic answers for Idiopathic pulmonary fibrosis (IPF) and only two pharmacological treatments have a marketing authorization for this disease. Recently nintedanib (Ofev®) has been authorized as a new therapeutic option and its economic profile has been evaluated by international Health Technology Assessment (HTA) bodies. IPF has important implications for everyday life of patients and their carers, negatively influencing their quality of life and bringing heavy economic burden to the NHS and to the entire society. It is, therefore important to consider these aspects for the Italian environment and to perform a pharmacoeconomic evaluation to define the efficiency of nintedanib in IPF by means of a Cost-Utility Analysis (CUA). As IPF is a chronic and progressive disease, a lifetime Markov model has been therefore developed with health states describing the patient’s condition as a combination of lung function and exacerbation history. The cohort entered in the model at different Forced Vital Capacity (FVC%) predicted health states, without exacerbation. The Clinical data used to perform this CUA were derived from clinical trials and the relative efficacy of nintedanib versus the comparator (pirfenidone) was then obtained from a Network Meta-Analysis (NMA) combining data reported in each primary study (INPULSIS 1-2 and TOMORROW trials for nintedanib, and CAPACITY and ASCEND trials for pirfenidone, respectively). At base-case, treatment with nintedanib resulted in a slightly lower estimated total cost vs pirfenidone, better safety profile and lower risk of acute exacerbations with an advantage in Quality Adjusted Life years (QALYs) gained. These results were confirmed by the sensitivity analysis. Although nintedanib appears to be a valuable option for the NHS to treat IPF patients, future data evidence, as long-term or real-life data, will help to confirm these results.
[In Italian]
References
Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129-37; https://doi.org/10.1378/chest.09-1002
Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355-61; https://doi.org/10.1183/09059180.00002512
Caminati A, Madotto F, Cesana G, et al. Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. Eur Respir Rev 2015; 24: 436-44; https://doi.org/10.1183/16000617.0040-2015
Kaunisto J, Salomaa ER, Hodgson U, et al. Idiopathic pulmonary fibrosis - a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 2013; 13: 53; https://doi.org/10.1186/1471-2466-13-53
Lai CC, Wang CY, Lu HM, et al. Idiopathic pulmonary fibrosis in Taiwan - a population-based study. Respir Med 2012; 106: 1566-74; https://doi.org/10.1016/j.rmed.2012.07.012
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788-824; https://doi.org/10.1164/rccm.2009-040GL
Gribbin J, Hubbard RB, Le Jeune I, et al Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-5; https://doi.org/10.1136/thx.2006.062836
Agabiti N, Porretta MA, Bauleo L, et al. Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 191-7
Harari S, Madotto F, Caminati A, et al. Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy. PLoS One 2016; 11: e0147072; https://doi.org/10.1371/journal.pone.0147072
Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8; https://doi.org/10.1186/1750-1172-3-8
Vancheri C, Failla M, Crimi N, et al. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J 2010; 35: 496-504; https://doi.org/10.1183/09031936.00077309
Vancheri C. Idiopathic pulmonary fibrosis: an altered fibroblast proliferation linked to cancer biology. Proc Am Thorac Soc 2012; 9: 153-7; https://doi.org/10.1513/pats.201203-025AW
Cottin V. Interstitial lung disease. Eur Respir Rev 2013; 22: 26-32; https://doi.org/10.1183/09059180.00006812
Adkins JM, Collard HR. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2012; 33: 433-9; https://doi.org/10.1055/s-0032-1325154
Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431-40; https://doi.org/10.1164/rccm.201006-0894CI
Kim DS, Collard HR, King TE Jr. Classification and natural history of idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006; 3: 285-92; https://doi.org/10.1513/pats.200601-005TK
Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277-84; https://doi.org/10.1164/rccm.200701-044OC
Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-7; https://doi.org/10.1164/rccm.200705-656OC
Du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 141-6; https://doi.org/10.1183/09059180.00000812
Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 2013; 14 Suppl 1: S5; https://doi.org/10.1186/1465-9921-14-S1-S5
Leslie KO, Cool CD, Sporn TA, et al. Familial idiopathic interstitial pneumonia: histopathology and survival in 30 patients. Arch Pathol Lab Med 2012; 136: 1366-76; https://doi.org/10.5858/arpa.2011-0627-OAI
Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011; 37: 356-63; https://doi.org/10.1183/09031936.00159709
Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 636-43; https://doi.org/10.1164/rccm.200703-463PP
Hyldgaard C, Hilberg O, Bendstrup E. How does co-morbidity influence survival in idiopathic pulmonary fibrosis? Respir Med 2014; 108: 647-53; https://doi.org/10.1016/j.rmed.2014.01.008
King C, Nathan SD. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. Curr Opin Pulm Med 2013; 19: 466-73; https://doi.org/10.1097/MCP.0b013e328363f460
Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129: 746-52; https://doi.org/10.1378/chest.129.3.746
Tomassetti S, Gurioli C, Ryu J, et al. The impact of lung cancer on survival of Idiopathic Pulmonary Fibrosis. Chest 2015; 147: 157-64; https://doi.org/10.1378/chest.14-0359
Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis. A population based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8; https://doi.org/10.1164/ajrccm.161.1.9906062
Navaratnam V, Fogarty AV, McKeever T, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax 2014; 69: 207-15; https://doi.org/10.1136/thoraxjnl-2013-203740
Bargagli E, Madioni C, Bianchi N, et al. Serum analysis of coagulation factors in IPF and NSIP. Inflammation 2014; 37: 10-6; https://doi.org/10.1007/s10753-013-9706-z
Harris JM, Johnston ID, Rudd R, et al. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2009; 65: 70-6; https://doi.org/10.1136/thx.2009.121962
Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology 2009; 14: 723-8; https://doi.org/10.1111/j.1440-1843.2009.01547.x
Tomassetti S, Albera C, Aronne D, et al. Documento AIPO-SIMeR sulla Fibrosi Polmonare Idiopatica. Rassegna di Patologia dell’Apparato Respiratorio 2015; 30(Suppl. 1): 3-31
Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609-16; https://doi.org/10.1378/chest.10-0608
Alakhras, Decker PA, Nadrous HF, et al. Body mass index and mortality in patients with idiopathic pulmonary fibrosis. Chest 2007; 131: 1448-53; https://doi.org/10.1378/chest.06-2784
Kim JH, Lee JH, Ryu YJ, et al. Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis 2012; 73: 162-8; https://doi.org/10.4046/trd.2012.73.3.162
Gribbin J, Hubbard R, Smith C. Role of diabetes mellitus and gastrooesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respir Med 2009; 103: 927-31; https://doi.org/10.1016/j.rmed.2008.11.001
Mermigkis C, Stagaki E, Tryfon S, et al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath 2010; 14: 387-90; https://doi.org/10.1007/s11325-010-0336-5
Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung 2007; 185: 173-8; https://doi.org/10.1007/s00408-007-9004-3
Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 2009; 136: 772-8; https://doi.org/10.1378/chest.08-2776
Sweet MP, Patti MG, Leard LE, et al. Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg 2007; 133: 1078-84; https://doi.org/10.1016/j.jtcvs.2006.09.085
Han MK. High prevalence of abnormal acid gastrooesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006; 28: 884-5; https://doi.org/10.1183/09031936.06.00071806
Tcherakian C, Cottin V, Brillet PY, et al. Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax 2011; 66: 226-31; https://doi.org/10.1136/thx.2010.137190
Lee J, Song J, Wolters P, et al. Bronchoalveolar lavage pepsin levels in acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 1698-702; https://doi.org/10.1164/rccm.201010-1752OC
Vancheri C. Gastro-oesophageal reflux and idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30S: 37-9
Bennett D, Bargagli E, Refini RM, et al. Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis. Eur Respir J 2014; 43: 635-8; https://doi.org/10.1183/09031936.00104813
Chilosi M, Poletti V, Rossi A. The pathogenesis of COPD and IPF: two horns of the same devil? Respir Res 2012; 13: 3; https://doi.org/10.1186/1465-9921-13-3
Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptiblity loci for pulmonary fibrosis. Nature Genetics 2013; 45: 613-20; https://doi.org/10.1038/ng.2609
Cottin V, Nunes H, Brillet P, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. EurRespir J 2005; 26: 586-9; https://doi.org/10.1183/09031936.05.00021005
Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136: 10-5; https://doi.org/10.1378/chest.08-2306
Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest 2013; 144: 234-40; https://doi.org/10.1378/chest.12-2403
Adir Y, Harari S. Pulmonary hypertension associated with chronic obstructive lung disease and idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2014; 20: 414-20; https://doi.org/10.1097/MCP.0000000000000084
Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant transplant. Eur Respir J 2007; 30: 715-21; https://doi.org/10.1183/09031936.00107206
Agarwal R, Gupta D, Verma JS, et al. Noninvasive estimation of clinically asymptomatic pulmonary hypertension in idiopathic pulmonary fibrosis. Indian J Chest Dis Allied Sci 2005; 47: 267-7
Nadrous HF, Pellikka PA, Krowka MJ, et al. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005; 128: 616S-7S; https://doi.org/10.1378/chest.128.6_suppl.616S
Castria D, Refini RM, Bargagli E, et al. Pulmonary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immunopathol Pharmacol 2012; 25: 681-9; https://doi.org/10.1177/039463201202500314
Raghu G, Rochwerg B, Zhang Y, et al. American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3-19; https://doi.org/10.1164/rccm.201506-1063ST
Noth I, Anstrom KJ, Calvert SB, et al . A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95; https://doi.org/10.1164/rccm.201202-0314OC
Raghu G, Anstrom KJ, King J, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-77; https://doi.org/10.1056/NEJMoa1113354
Martinez FJ, Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Eng J Med 2014, 370: 2093-100; https://doi.org/10.1056/NEJMoa1401739
Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005; 171: 1040-7; https://doi.org/10.1164/rccm.200404-571OC
Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone Clinical Study Group in Japan. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 821-9; https://doi.org/10.1183/09031936.00005209
Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760-9; https://doi.org/10.1016/S0140-6736(11)60405-4
King TE Jr, Bradford WZ, Castro-Bernardini S, et al.; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-92; https://doi.org/10.1056/NEJMoa1402582
Collard HR, Ward AJ, Lanes S, et al. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 2012; 15: 829-35; https://doi.org/10.3111/13696998.2012.680553
Raimundo K , Chang E, Broder M, et al. Clinical And Economic Burden Of Idiopathic Pulmonary Fibrosis. American Thoracic Society 2015 International Conference. Denver, May 15-20, 2015. MeetingAbstracts.A2521
Brun M, Luedtke D, Klüglich M, et al. A 52 week, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capacity decline during one year, in patients with Idiopathic Pulmonary Fibrosis, with optional active treatment extension until last patient out. Anno 2011. Data on file
Collard HR, Chen SY, Yeh WS, et al. Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Ann Am Thorac Soc 2015; 12: 981-7; https://doi.org/10.1513/AnnalsATS.201412-553OC
Navaratnam V, Fogarty AW, Glendening R, et al. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013; 143: 1078-84; https://doi.org/10.1378/chest.12-0803
Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462-7; https://doi.org/10.1136/thx.2010.148031
Wuyts W, Peccatori FA, Russell AM. Patient-centred management in idiopathic pulmonary fibrosis:similar themes in three communications models. Eur Respir Rev 2015; 23: 231-8; https://doi.org/10.1183/09059180.00001614
Crestani B. European IPF Patient Charter: an SOS to the world. Eur Respir J 2016; 47: 403-5; https://doi.org/10.1183/13993003.01902-2015
Duck A, Spencer LG, Bailey S, et al. Perceptions,experience and needs of patients with idiopathic pulmonary fibrosis. J Adv Nurs 2015; 71: 1055-65; https://doi.org/10.1111/jan.12587
Sampson C, Gill BH, Harrison NK, et al. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med 2015; 15: 155; https://doi.org/10.1186/s12890-015-0145-5
Yorke J, Spencer LG, Duck A, et al. Cross-Atlantic modification and validation of the A tool to assess Quality of Life in idiopathic pulmonary fibrosis (ATAQ-IPF-cA) BMJ Open Resp Res 2014; 1: e000024; https://doi.org/10.1136/bmjresp-2014-000024
Yount SE, Beamumont JL, Kaiser K, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung 2016; 194: 227-34; https://doi.org/10.1007/s00408-016-9850-y
Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients’perpectives of the disease and treatment. BMC Pulm Med 2016; 16: 10; https://doi.org/10.1186/s12890-016-0171-y
Bonella F, Wijsenbeek M, Molina-Molina M , et al. European IPF Patient Charter: unmeets needs and a call to action for healthcare polimakers. Eur respir J 2016; 47: 597-606; https://doi.org/10.1183/13993003.01204-2015
Ofev – Summry of product characteristics. Disponibile su: http://ec.europa.eu/health/documents/community-register/2015/20150115130436/anx_130436_en.pdf (Ultimo accesso Novembre 2016)
Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther 2014; 31: 375-91; https://doi.org/10.1007/s12325-014-0112-1
Cottin V. Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clin Invest 2015; 5: 621-32; https://doi.org/10.4155/cli.15.27
Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079-87; https://doi.org/10.1056/NEJMoa1103690
Richeldi L, du Bois MD, Raghu G et al. Efficacy and Safety of Ofev® (nintedanib) in Idiopathic Pulmonary Fibrosis. N Engl J Med 2014; 370: 2071; https://doi.org/10.1056/NEJMoa1402584
Bonella F, Stowasser S, Wollin L. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther 2015; 9: 6407-19
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010; 35: 830-6; https://doi.org/10.1183/09031936.00155108
Du Bois RM, Weycker D, Albera C, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011; 184: 1382-9; https://doi.org/10.1164/rccm.201105-0840OC
Saydain G, Islam A, Afessa B, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit. Am J Respir Crit Care Med 2002; 166: 839-42; https://doi.org/10.1164/rccm.2104038
Richeldi L, Cottin V, du Bois RM, et al. Ofev® (nintedanib) in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials. Respir Med 2016; 113: 74-9; https://doi.org/10.1016/j.rmed.2016.02.001
Kolb M, Kimura T, Stowasser S, et al. Effect of baseline FVC on decline in lung function with nintedanib in patients with IPF: results from the INPULSIS® trials. Thorax 2015; 70: A62; https://doi.org/10.1136/thoraxjnl-2015-207770.114
Costabel U, Inoue Y, Richeldi L, et al. Efficacy of Ofev® (nintedanib) in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-85; https://doi.org/10.1164/rccm.201503-0562OC
Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2016; pii: thoraxjnl-2016-208710; https://doi.org/10.1136/thoraxjnl-2016-208710
Raghu G, Wells AU, Nicholson AG, et al. Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med 2017; 195: 78-85; https://doi.org/10.1164/rccm.201602-0402OC
NICE – Appraisal consultation document. Nintedanib for treating idiopathic pulmonary fibrosis 2015. Disponibile su https://www.nice.org.uk/guidance/TA379/documents/idiopathic-pulmonary-fibrosis-nintedanib-id752-appraisal-consultation-document2 (ultimo accesso luglio 2016)
Loveman E, Copley VR, Colquitt J, et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 2015; 19; https://doi.org/10.3310/hta19200
Rochwerg B, Neupane B, Zhang Y, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016; 14: 18; https://doi.org/10.1186/s12916-016-0558-x
Canestaro WJ, Forrester SH, Raghu G, et al. Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. Chest 2016; 149: 756-66; https://doi.org/10.1016/j.chest.2015.11.013
Collard HR, King J, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 538-42; https://doi.org/10.1164/rccm.200211-1311OC
Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiologic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003; 168: 543-8; https://doi.org/10.1164/rccm.200209-1112OC
King J, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005; 127: 171-7; https://doi.org/10.1378/chest.127.1.171
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003; 168: 531-7; https://doi.org/10.1164/rccm.200210-1245OC
Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011; 14: 539-45; https://doi.org/10.1016/j.jval.2010.10.029
NICE Single Technology Appraisal (review TA282). Available at: https://www.nice.org.uk/guidance/GID-TAG504/documents/committee-papers (ultimo accesso luglio 2016)
Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007; 11; https://doi.org/10.3310/hta11510
Tariffe delle prestazioni di assistenza ospedaliera per acuti (sistema DRG). Supplemento ordinario n. 8 alla Gazzetta Ufficiale Serie generale - n. 23 del 28-1-2013
Ministero della Salute. Rapporto sull’attività di ricovero ospedaliero 2014. Disponibile su http://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2396 (ultimo accesso luglio 2016)
Regione Veneto. Applicazione DRG 1411 del 6/9/2011 ad oggetto “Oneri dei servizi di soccorso e trasporto sanitario. Modifica alla circolare n. 12 del 4/5/1999 di cui alle deliberazioni della giunta regionale n. 1490 del 4/5/1999 e n. 1527 del 15/6/2001. Disponibile su http://www.mediatec.it/ipertesto/REGIONI/Veneto/AmbulanzaRegole2012.pdf (ultimo accesso luglio 2016)
Ministero della Salute. Progetto Mattoni SSN. Pronto Soccorso e Sistema 118. “Proposta metodologica per la valutazione dei costi dell’emergenza” Roma 2007
ASL 3 Liguria. Rimborsi visite occasionali. Disponibile su http://www.asl3.liguria.it/ambulatori/servizi/cure-primarie/item/197-rimborsi-visite-occasionali.html (ultimo accesso luglio 2016)
Riabilitazione Respiratoria alla MultiMedica di Limbiate. Disponibile su http://www.multimedica.it/it/news/riabilitazione-respiratoria-alla-multimedica-di-limbiate/66faadb9-ad1a-4625-8f39-ab458affc1f1 (ultimo accesso luglio 2016)
Regione Emilia Romagna. Altre prestazioni. Disponibile su www.aosp.bo.it/files/altreprestazioni_0.pdf (ultimo accesso luglio 2016)
Clini EM, Magni G, Crisafulli E, et al. Home non-invasive mechanical ventilation and long-term oxygen therapy in stable hypercapnic chronic obstructive pulmonary disease patients: comparison of costs. Respiration 2009; 77: 44-50
Scottish Medicines Consortium – SMC. Nintedanib 100mg and 150mg capsules (Ofev®). SMC No. (1076/15). Disponibile su https://www.scottishmedicines.org.uk/files/advice/nintedanib__Ofev__FINAL_September_2015_Amended_06.10.15_for_website.pdf (ultimo accesso luglio 2016)
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
